Prior Axitinib as a Determinant of Outcome of Renal Surgery

NCT03438708 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG: Axitinib Oral Tablet [Inlyta]

Sponsor

University of California, San Diego

Collaborators

[object Object]